Abiomed, Biosense Webster, Cerenovus now all known as Johnson & Johnson MedTech
Johnson & Johnson has officially completed a major transition, announcing that Biosense Webster, Abiomed, Cerenovus and some of its other healthcare technology companies will now go by the name Johnson & Johnson MedTech.
Johnson & Johnson first announced its agreement to acquire Biosense Webster for $400 million in shares back in 1997, and Cerenovus was launched in 2017 after the company combined its acquisitions of Pulsar Vascular and Neuravi. The decision to buy Abiomed, meanwhile, came in November 2022.
Now, these companies—in addition to Ethicon and DePuy Synthes—are all under the Johnson & Johnson umbrella.
“By bringing our medtech businesses together under the Johnson & Johnson name, the scale of our impact in healthcare will be even more apparent, unlocking new opportunities for us to strengthen our competitiveness,” Tim Schmid, Johnson & Johnson executive vice president and worldwide chairman of medtech, said in a statement. “While Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and Cerenovus will now go by Johnson & Johnson MedTech, we will continue to honor the legacies of these brands by maintaining the products, services and approach to collaboration that made them some of the most trusted names in healthcare.”
This change is expected to hit social media pages and other marketing materials in the weeks ahead. The company emphasized that this “will have no impact on the Johnson & Johnson MedTech portfolio.”
How the move impacts other recent acquisitions
In May, Johnson & Johnson finalized its acquisition of Shockwave Medical, the California-based company known for its intravascular lithotripsy technology, for $13 billion. While it is now operating as a business unit within Johnson & Johnson MedTech, it was not one of the companies included in this latest name change announcement.
Another recently announced Johnson & Johnson transaction, the company’s acquisition of V-Wave for up to $1.7 billion, has not yet been finalized.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.